Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 401–500 of 1,002
Lee, J.-H., Lau, K.-F., Perkinton, M. S., Standen, C. L., Shemilt, S. J. A., Mercken, L., Cooper, J. D., McLoughlin, D. M., & Miller, C. C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300503200 · Cited by 86
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 86
Intramembrane proteolysis by presenilin and presenilin-like proteases
Xia, W., & Wolfe, M. S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00651 · Cited by 82
Self-citationMattson, M. P., Lee, J., & Chan, S. L. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:1:29 · Cited by 90
“Two abnormalities caused by PS1 mutations that are believed to promote neuronal dysfunction and degeneration are increased production of a neurotoxic form of A (A 42) (Scheuner et al., 1996; Citron et al., 1997; Guo et al., 1999a) and disruption of endoplasmic reticulum calcium homeostasis (Guo et al.”
BackgroundPresenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities
O’Riordan, S., McMonagle, P., Janssen, J. C., Fox, N. C., Farrell, M., Collinge, J., Rossor, M. N., & Hutchinson, M. (2002) · Neurology · doi:10.1212/wnl.59.7.1108 · Cited by 83
Guglielmotto, M., Tamagno, E., & Danni, O. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.93 · Cited by 82
Rofina, J., Singh, K., Skoumalova-Vesela, A., van Ederen, A. M., van Asten, A. J., Wilhelm, J., & Gruys, E. (2004) · Amyloid · doi:10.1080/13506120412331285779 · Cited by 84
Westlund, B., Parry, D., Clover, R., Basson, M., & Johnson, C. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2497 · Cited by 82
Mulligan, V. K., & Chakrabartty, A. (2013) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24285 · Cited by 81
Mckean, N. E., Handley, R. R., & Snell, R. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313168 · Cited by 88
ROCKENSTEIN, E., CREWS, L., & MASLIAH, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.013 · Cited by 65
Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age
Abdul, H. M., Sultana, R., St. Clair, D. K., Markesbery, W. R., & Butterfield, D. A. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.08.012 · Cited by 81
“Insights into potential disease mechanisms of AD have been facilitated by the discovery of the genetic mutations that underlie inherited forms of early onset AD [7,8].”
BackgroundThe state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease
Rottkamp, C. A., Atwood, C., Joseph, J. A., Nunomura, A., Perry, G. L., & Smith, M. A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00069-4 · Cited by 87
“[25] Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et”
BackgroundShioi, J., Georgakopoulos, A., Mehta, P., Kouchi, Z., Litterst, C. M., Baki, L., & Robakis, N. K. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04391.x · Cited by 79
“…increasing APP processing and production of neurotoxic peptide Ab 42 that promotes cerebral amyloidosis (Borchelt et al. 1996; Scheuner et al. 1996; Citron et al. 1997) and formation of Ab oligomers [for review see Klein et al. (2001), Chan et al. (2002), Hardy and Selkoe (2002), Koo and Kopan…”
BackgroundResultInfluentialHole, K. L., & Williams, R. J. (2020) · Brain Plasticity · doi:10.3233/bpl-200098 · Cited by 82
Intracellular A-Beta Amyloid, A Sign for Worse Things to Come?
Echeverria, V., & Cuello, A. C. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:299 · Cited by 63
O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease
Park, J., Lai, M. K. P., Arumugam, T. V., & Jo, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08584-0 · Cited by 85
Whalen, B. M., Selkoe, D. J., & Hartley, D. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.007 · Cited by 89
“…and presenilin-2 genes and in the amyloid-h protein precursor (APP) gene alter Ah production, most notably by increasing the production of the highly amyloidogenic Ah1–42 form of the peptide (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Scheuner et al., 1996; Tomita et al., 1997).”
BackgroundSelf-citationComparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease
Hellström‐Lindahl, E., Viitanen, M. H., & Marutle, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.03.007 · Cited by 89
Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900026 · Cited by 78
“Previous studies using PS1 mutant-transgenic mice report that the magnitude of the increase in the relative A b 42 level in cultured cells reflect the magnitude of increase in the brain (Borchelt et al, 1996; Citron et al, 1997).”
Dewachter, I., Dorpe, J. V., Spittaels, K., Tesseur, I. C., den Haute, C. V., Moechars, D., & LEUVEN, F. V. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00149-2 · Cited by 82
“This appeared speci®c as it was not observed for the 85 kDa subunit of the Lipoprotein Receptor related protein (LRP) (Dewachter, 2000).”
InfluentialPhenotypic and functional changes in glial cells as a function of age
Yu, W. H., Go, L., Guinn, B., Fraser, P. E., Westaway, D. A., & McLaurin, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00258-5 · Cited by 85
Self-citationTomita, T., Tokuhiro, S., Hashimoto, T., Aiba, K., Saido, T. C., Maruyama, K., & Iwatsubo, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.21153 · Cited by 78
Soto, C. A. (1999) · Journal of Molecular Medicine · doi:10.1007/s001090050371 · Cited by 87
β-Peptide Immunization: A Possible New Treatment for Alzheimer Disease
Schenk, D. B., Seubert, P., Lieberburg, I., & Wallace, J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.7.934 · Cited by 77
Self-citationWang, X.-L., Zeng, J., Feng, J., Tian, Y.-T., Liu, Y.-J., Qiu, M., Yan, X., Yang, Y., Xiong, Y., Zhang, Z.-H., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00066 · Cited by 74
“It is well known that gene mutations of presenilin (PS)-1 and PS-2, key protein members of γ-secretase, are causative for increased Aβ production in familial AD (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Xia et al., 1997).”
BackgroundThe amyloid precursor protein of Alzheimer disease in human brain and blood
Li, Q.-X., Fuller, S. J., Beyreuther, K., & Masters, C. L. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.4.567 · Cited by 77
Discovery and development of biomarkers of neurological disease
Dunckley, T. L., Coon, K. D., & Stephan, D. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03353-7 · Cited by 77
Presenilin transgenic mice as models of Alzheimer’s disease
Elder, G. A., Sosa, M. A. G., Gasperi, R. D., Dickstein, D. L., & Hof, P. R. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0227-3 · Cited by 84
“…APP FAD mutant mice, compared to the parental APP FAD lines the ratio of Ab42/40 increases and plaque deposition begins at an earlier age and is more extensive with aging (Borchelt et al. 1997; Citron et al. 1997; Holcomb et al. 1998; Lamb et al. 1999; McGowan et al. 1999; Dewachter et al. 2000).”
Single cell gene expression profiling in Alzheimer’s disease
Ginsberg, S. D., Che, S., Counts, S., & Mufson, E. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.007 · Cited by 79
“Cell culture and transgenic mouse studies have also detected an interaction between mutations in the PSEN1 and PSEN2 genes observed in FAD kindreds and increased production of the amyloidogenic A fragment [A (1–42)].(46,56,57) Specifically, an increased ratio of A (1–42)/A (1–40) caused by defective presenilins may ac…”
BackgroundRusso, C., Salis, S., Dolcini, V., Venezia, V., Song, X., Teller, J. K., & Schettini, G. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0357 · Cited by 75
Cacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
“transgenic animals with FAD-linked PS1 mutations show increasing brain levels of Ab1–42 [15,38].”
BackgroundResultAPOA1 polymorphism influences risk for early-onset nonfamiliar AD
Vollbach, H., Heun, R., Morris, C. M., Edwardson, J. A., McKeith, I. G., Jessen, F., Schulz, A., Maier, W., & Kölsch, H. (2005) · Annals of Neurology · doi:10.1002/ana.20593 · Cited by 74
“Autosomal dominant mutations in the genes encoding the amyloid precursor protein on chromosome 21 and presenilins 1 and 2 (chromosomes 14 and 1) have been identified to cause rare familial early-onset AD (EOAD).(1,2) Until now, the only proven genetic risk factor for sporadic late-onset AD (LOAD) is the presence of at…”
BackgroundImplication of APP Secretases in Notch Signaling
Hartmann, D., Tournoy, J., Säftig, P., Annaert, W. G., & Strooper, B. D. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:171 · Cited by 76
“…PS2; http://molgen-www.uia.ac.be/ADmutations/) modify the γ-secretase cleavage of APP, causing the generation of a higher proportion of the less soluble Aβ1-42 as compared to the otherwise predominating Aβ1-40 (Scheuner et al., 1996; Duff et al., 1996; Citron et al., 1997; Borchelt et al., 1997).”
BackgroundSaura, C. A., Tomita, T., Davenport, F., Harris, C. L., Iwatsubo, T., & Thinakaran, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13818 · Cited by 75
Accumulation of murine amyloidβ42 in a gene‐dosage‐dependent manner in PS1 ‘knock‐in’ mice
Nakano, Y., Kondoh, G., Kudo, T., Imaizumi, K., Kato, M., Miyazaki, J., Tohyama, M., Takeda, J., & Takeda, M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00698.x · Cited by 70
Tysoe, C. J., Whittaker, J., Xuereb, J. H., Cairns, N. J., Cruts, M., Broeckhoven, C. V., Wilcock, G. K., & Rubinsztein, D. C. (1998) · The American Journal of Human Genetics · doi:10.1086/301672 · Cited by 74
“…lines transfected with familial presenilin mutations have increased production of the amyloidogenic 42-residue amyloid b-peptide, whereas no such effect was seen when the mice or the cell lines were transfected with the wild-type gene (Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997).”
BackgroundCathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
Suire, C. N., Abdul-Hay, S. O., Sahara, T., Kang, D., Brizuela, M. K., Saftig, P., Dickson, D. W., Rosenberry, T. L., & Leissring, M. A. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00649-8 · Cited by 73
“2c), an increase comparable in scale to that induced by many AD-linked presenilin mutations [29, 32, 33].”
Terro, F., Czech, C., Esclaire, F., Elyaman, W., Yardin, C., Baclet, M., Touchet, N., Tremp, G., Pradier, L., & Hugon, J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10312 · Cited by 72
“The mechanisms whereby mutations in ps1 and ps2 genes cause AD also remain elusive, but several lines of evidence suggest that they play a key role in modulating A 42 production (Citron et al., 1997; Tomita et al., 1997).”
BackgroundCortical Neuronal and Glial Pathology in TgTauP301L Transgenic Mice
Murakami, T., Paitel, E., Kawarabayashi, T., Ikeda, M., Chishti, M. A., Janus, C., Matsubara, E., Sasaki, A., Kawarai, T., Phinney, A. L., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051250 · Cited by 78
Self-citationKitazawa, M., Green, K. N., Caccamo, A., & LaFerla, F. M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051232 · Cited by 80
Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease
Wahlster, L., Arimon, M., Nasser‐Ghodsi, N., Post, K. L., Serrano‐Pozo, A., Uemura, K., & Berezovska, O. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1065-6 · Cited by 77
“It has been proposed that the longer and more aggregation-prone Ab species, such as Ab42 or Ab43, are implicated in neurotoxicity linked to AD [11, 55].”
CD 4 T cells in immunity and immunotherapy of Alzheimer's disease
Monsonego, A., Nemirovsky, A., & Harpaz, I. (2013) · Immunology · doi:10.1111/imm.12103 · Cited by 70
Genetic risk factors in Alzheimer's disease.
Tilley, L. A., Morgan, K., & Kalsheker, N. A. (1998) · Molecular Pathology · doi:10.1136/mp.51.6.293 · Cited by 88
Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives
Robakis, N. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.022 · Cited by 72
Li, J., Pauley, A. M., Myers, R. L., Shuang, R., Brashler, J. R., Yan, R., Buhl, A. E., Ruble, C., & Gurney, M. E. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01105.x · Cited by 72
“The presenilins play a role in the production of amyloid b-peptide (Ab) from the amyloid protein precursor (APP) (Borchelt et al. 1996; Citron et al. 1997).”
BackgroundMethodNovel Class of Polytopic Proteins with Domains Associated with Putative Protease Activity
Grigorenko, A. P., Moliaka, Y., Коровайцева, Г. И., & Rogaev, E. I. (2002) · Biochemistry (Moscow) · doi:10.1023/a:1016365227942 · Cited by 77
A cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor
Liu, L., Ding, L., Rovere, M., Wolfe, M. S., & Selkoe, D. J. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201806205 · Cited by 64
Self-citationExploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Setu, J. R., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00232-x · Cited by 78
Jolly-Tornetta, C., Gao, Z.-Y., Lee, V. M.-Y., & Wolf, B. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.14015 · Cited by 73
Presenilin 1 is Actively Degraded by the 26S Proteasome
Fraser, P. E., Lévesque, G., Yu, G., Mills, L. R., Thirlwell, J., Frantseva, M. V., Gandy, S., Seeger, M., Carlen, P. L., & George‐Hyslop, P. S. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00029-3 · Cited by 77
Self-citationYu, G., Chen, F., Nishimura, M., Steiner, H., Tandon, A., Kawarai, T., Arawaka, S., Supala, A., Song, Y., Rogaeva, E. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61517-6 · Cited by 76
Self-citationCecchi, C., Rosati, F., Pensalfini, A., Formigli, L., Nosi, D., Liguri, G., Dichiara, F., Morello, M., Danza, G., Pieraccini, G., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00216.x · Cited by 70
“A 40 and A 42 peptides arise from intracellular processing of APP carried out by BACE and -secretase in the amyloidogenic pathway [1–3].”
BackgroundHeilig, E. A., Gutti, U., Tai, T., Shen, J., & Kelleher, R. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0954-13.2013 · Cited by 69
“WT PS1 cDNA expression vector (pCZ-PS1) and expression vectors for PS1 bearing C410Y or ex9 mutations were kindly provided by W. Xia (Brigham and Women’s Hospital) and have been previously described (Citron et al., 1997).”
MethodFamilial clustering and genetic risk for dementia in a genetically isolated Dutch population
Sleegers, K., Roks, G., Theuns, J., Aulchenko, Y. S., Rademakers, R., Cruts, M., van Gool, W. A., Van Broeckhoven, C., Heutink, P., Oostra, B. A., et al. (2004) · Brain · doi:10.1093/brain/awh179 · Cited by 69
“Based on the results obtained in the linkage analysis, patients and 120 controls were genotyped for the A2M insertiondeletion (I/D) polymorphism (Matthijs and Marynen, 1991) and three STR markers on chromosome 10 (D10S192, D10S538 and D10S1686) surrounding the location of IDE.”
BackgroundZinc and Health: Current Status and Future Directions
Hambidge, M. (2000) · Cited by 86
Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice
Rodrigo, J., Fernández‐Vizarra, P., Castro‐Blanco, S., Bentura, M. L., Nieto, M., Gómez‐Isla, T., Martínez‐Murillo, R., Martínez, A., Serrano, J., & Fernández, A. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.030 · Cited by 77
Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF
Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 70
Self-citationYamada, M., Chiba, T., Sasabe, J., Nawa, M., Tajima, H., Niikura, T., Terashita, K., Aiso, S., Kita, Y. A., Matsuoka, M., et al. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.03.026 · Cited by 69
Choi, E., Zaidi, N. F., Miller, J. S., Crowley, A. C., Merriam, D. E., Lilliehöök, C., Buxbaum, J. D., & Wasco, W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008597200 · Cited by 72
Shirotani, K., Tomioka, M., Kremmer, E., Haass, C., & Steiner, H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.011 · Cited by 69
Lee, J.-H., Lau, K.-F., Perkinton, M. S., Standen, C. L., Rogelj, B., Falinska, A., McLoughlin, D. M., & Miller, C. C. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405602200 · Cited by 68
Ghribi, O., Herman, M. M., & Savory, J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10511 · Cited by 67
“Transgenic mice with mutated amyloid precursor protein, the precursor of A , can develop A deposits (Duff et al., 1996; Citron et al., 1997; Gau et al., 2002) but NFTs have not been detected (Games et al., 1995; Gau et al., 2002).”
BackgroundQuantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.
Iljina, M., Garcia, G. A., Dear, A. J., Flint, J., Narayan, P., Michaels, T. C. T., Dobson, C. M., Frenkel, D., Knowles, T. P. J., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep28658 · Cited by 68
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Grösgen, S., Haupenthal, V. J., Blümel, T., Hundsdörfer, B., Zimmer, V. C., Mylonas, N. T., Tanila, H., et al. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00077 · Cited by 65
Kawasumi, M., Chiba, T., Yamada, M., Miyamae‐Kaneko, M., Matsuoka, M., Nakahara, J., Tomita, T., Iwatsubo, T., Kato, S., Aiso, S., et al. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03397.x · Cited by 72
Amyloid-β Metal Interaction and Metal Chelation
Cuajungco, M. P., Frederickson, C. J., & Bush, A. I. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_12 · Cited by 71
Barkats, M., Millecamps, S., Abrioux, P., Geoffroy, M., & Mallet, J. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751438.x · Cited by 75
Mollenhauer, B., Bibl, M., Trenkwalder, C., Stiens, G., Cepek, L., Steinacker, P., Ciesielczyk, B., Neubert, K., Wiltfang, J., Kretzschmar, H. A., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0235-7 · Cited by 69
“…Belgien; p-tau: INNOTESTTM PHOSPHO-TAU(181P); Ab42: INNOTESTTH b-AMYLOID(1–42), Innogenetics, Gent, Belgien; Ab40: hAmyloid b40 Elisa ABETA GmbH, Heidelberg, Germany; S-100B: LIA-mat Sangtec 100, Bromma, Sweden) (Hulstaert et al., 1999; Otto et al., 1997; Citron et al., 1997; Aurell et al., 1998).”
Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease
Chauhan, N. B., Lee, J. M., & Siegel, G. J. (1997) · Journal of Molecular Neuroscience · doi:10.1007/bf02800498 · Cited by 75
“From the analysis of fibroblasts and plasma from subjects with the known gene mutations in familial AD and from the studies of transfected cells and brains of transgenic animals with these mutated genes, the principal and earliest known biochemical change is an increased elaboration of the A]3 peptide containing 42 re…”
BackgroundThe Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons
Berezovska, O., Frosch, M., McLean, P., Knowles, R., Koo, E., Kang, D., Shen, J., Lu, F. M., Lux, S. E., Tonegawa, S., et al. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00119-9 · Cited by 68
Pharmacology of epigenetics in brain disorders
Narayan, P., & Dragunow, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00526.x · Cited by 67
“The second cleavage is performed by g-secretase which is a PSEN (either PSEN1 or PSEN2)dependent enzyme (Citron et al., 1997; De Strooper et al., 1998), and produces the APP intracellular domain (AICD, also known as an APP C-terminal fragment, APP-CT) and either a 3 kDa protein (p3, when in combination with a-secretas…”
BackgroundPathogenesis of Alzheimer’s Disease
Castellani, R. J., & Perry, G. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_162 · Cited by 67
Progress toward valid transgenic mouse models for Alzheimer’s disease
Guénette, S. Y., & Tanzi, R. E. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00042-1 · Cited by 73
Parkin, E. T., Hussain, I., Karran, E. H., Turner, A. J., & Hooper, N. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721534.x · Cited by 68
Chong, C.-M., Ke, M., Tan, Y., Huang, Z., Zhang, K., Ai, N., Ge, W., Qin, D., Lu, J.-H., & Su, H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0945-7 · Cited by 66
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Bohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 63
“Thus missense, splice site or duplication mutants in the presenilin 1 (PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, which alter the levels or shift the balance of Aβ produced, are associatedwith rare, highly penetrant autosomal dominant forms of Familial Alzheimer's Disease (FAD).”
BackgroundSelf-citationErtekin-Taner, N., Ronald, J., Feuk, L., Prince, J., Tucker, M., Younkin, L., Hella, M., Jain, S., Hackett, A., Scanlin, L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi041 · Cited by 69
Early Onset Alzheimer’s Disease and Oxidative Stress
Meraz-Ríos, M. A., Franco-Bocanegra, D., Toral Rios, D., & Campos-Peña, V. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/375968 · Cited by 63
The structure and function of Alzheimer’s gamma secretase enzyme complex
Krishnaswamy, S., Verdile, G., Groth, D. M., Kanyenda, L. J., & Martins, R. N. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408360903335821 · Cited by 73
Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration
McInnes, J. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-12 · Cited by 64
“genes have been associated with the overproduction of Aβ by γ-secretase and lead to familial AD [70,71].”
BackgroundMaarouf, C. L., Daugs, I. D., Spina, S., Vidal, R., Kokjohn, T. A., Patton, R. L., Kalback, W. M., Luehrs, D. C., Walker, D. G., Castaño, E. M., et al. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-20 · Cited by 64
“It is widely accepted that a major pathological effect of PSEN mutations is a proportionately larger production of toxic Aβ42 [15-22].”
BackgroundPorayette, P., Gallego, M. J., Kaltcheva, M. M., Bowen, R. L., Vadakkadath Meethal, S., & Atwood, C. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.026328 · Cited by 61
Pellegrini, L., Passer, B. J., Canelles, M., Lefterov, I., Ganjei, J. K., Fowlkes, B. J., Koonin, E. V., & D'Adamio, L. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3203 · Cited by 65
The role of presenilins in Alzheimer’s disease
Thinakaran, G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8728 · Cited by 66
Amyloid-β 42 Activates the Expression of BACE1 Through the JNK Pathway
Guglielmotto, M., Monteleone, D., Giliberto, L., Fornaro, M., Borghi, R., Tamagno, E., & Tabaton, M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110884 · Cited by 63
“Mutations of presenilin 1 (PS1), the catalytic subunit of -secretase, are the most common genetic defect of early-onset familial AD and lead to an increased production of A 42 [2, 3].”
Calpain Dysregulation in Alzheimer’s Disease
Ferreira, A. (2012) · ISRN Biochemistry · doi:10.5402/2012/728571 · Cited by 62
“Of these peptides, Aβ1−42 is regarded as the main pathogenic species [122–130].”
BackgroundMatheou, C. J., Younan, N. D., & Viles, J. H. (2015) · Biochemical Journal · doi:10.1042/bj20141168 · Cited by 64
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A., & Lopera, F. (2016) · Colombia Medica · doi:10.25100/cm.v47i4.2640 · Cited by 63
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 78
“Mutations in PSEN1 was reported to change the activity of c-secretase complex, which finally leads to elevated Ab42 level as well as the ratio of Ab42 to Ab40 [15,16].”
BackgroundFišar, Z., Hansíková, H., Křížová, J., Jirák, R., Kitzlerová, E., Zvěřová, M., Hroudová, J., Wenchich, L., Zeman, J., & Raboch, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.013 · Cited by 75
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652489 · Cited by 66
Babiloni, C., Squitti, R., Percio, C. D., Cassetta, E., Ventriglia, M. C., Ferreri, F., Tombini, M., Frisoni, G. B., Binetti, G. G., Gurzì, M., et al. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.03.016 · Cited by 69
The Novel Presenilin-1-associated Protein Is a Proapoptotic Mitochondrial Protein
Xu, X., Shi, Y.-C., Gao, W., Mao, G., Zhao, G., Agrawal, S., Chisolm, G. M., Sui, D., & Cui, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209613200 · Cited by 64
Li, W., Li, W.-P., Yao, Y., Zhang, W., Yin, Y., Wu, G., & Gong, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.045 · Cited by 69
Inactivation of brain Cofilin-1 by age, Alzheimer's disease and γ-secretase
Barone, E., Mosser, S., & Fraering, P. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.004 · Cited by 72
Chakrabarti, S., Sinha, M., Thakurta, I., Banerjee, P., & Chattopadhyay, M. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990152 · Cited by 63
Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology
Shelkovnikova, T. A., Kulikova, A. A., Tsvetkov, P. O., Peters, O. M., Бачурин, С. О., Buchman, V. L., & Ninkina, N. N. (2012) · Molecular Biology · doi:10.1134/s0026893312020161 · Cited by 66
Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators
Bischoff, F., Berthelot, D., Cleyn, M. A. J. D., Macdonald, G. J., Minne, G., Oehlrich, D., Pieters, S., Surkyn, M., Trabanco, A. A., Tresadern, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201710f · Cited by 64
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.